Erratum: Angiogenesis in pituitary adenomas: Human studies and new mutant mouse models (International Journal of Endocrinology (2014) 2014 (608497) DOI: 10.1155/2014/608497);Angiogenesis in pituitary adenomas: Human studies and new mutant mouse models

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Cristina, Carolina ^a,b   Luque, Guillermina María ^a   Demarchi, Gianina ^b   Lopez Vicchi, Felicitas ^a   Zubeldia Brenner, Lautaro ^a   Perez Millan, Maria Ines ^a   Perrone, Sofia ^b   Ornstein, Ana Maria ^a   Lacau Mengido, Isabel M ^a   Berner, Silvia Inés ^c,d   Becu Villalobos, Damasia ^a  

^a CONICET ^*  (Argentina)

^b Universidad Nacional del Noroeste de la Provincia de Buenos Aires   (Argentina)

^c Division of Allergy and Immunology   (Argentina)

^d Hospital Oftalmologico Santa Lucia   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CD31 ANTIGEN; CD34 ANTIGEN; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE 5; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; THROMBOSPONDIN 1; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

3' UNTRANSLATED REGION; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFECT; DRUG TARGETING; HUMAN; HYPOPHYSIS ADENOMA; MOUSE MODEL; NONHUMAN; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84914693364     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2020/8978014     Document Type: Erratum

References (97)

1. Ferrara N., Davis-Smyth T., The biology of vascular endothelial growth factor. Endocrine Reviews 1997 18 1 4 25 10.1210/er.18.1.4 2-s2.0-0031039243
2. Schechter J., Ultrastructural changes in the capillary bed of human pituitary tumors. The American Journal of Pathology 1972 67 1 109 126 2-s2.0-0015326818
3. Jugenburg M., Kovacs K., Stefaneanu L., Scheithauer B. W., Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocrine Pathology 1995 6 2 115 124 10.1007/BF02739874 2-s2.0-51249161879
4. Turner H. E., Nagy Z., Gatter K. C., Esiri M. M., Harris A. L., Wass J. A. H., Angiogenesis in pituitary adenomas and the normal pituitary gland. The Journal of Clinical Endocrinology & Metabolism 2000 85 3 1159 1162 10.1210/jc.85.3.1159 2-s2.0-0034455008
5. Vidal S., Horvath E., Kovacs K., Lloyd R. V., Scheithauer B. W., Microvascular structural entropy: a novel approach to assess angiogenesis in pituitary tumors. Endocrine Pathology 2003 14 3 239 247 10.1385/EP:14:3:239 2-s2.0-0038427460
6. Turner H. E., Nagy Z., Gatter K. C., Esiri M. M., Harris A. L., Wass J. A. H., Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. Journal of Endocrinology 2000 165 2 475 481 10.1677/joe.0.1650475 2-s2.0-0034040426
7. Luque G. M., Perez-Millán M. I., Ornstein A. M., Cristina C., Becu-Villalobos D., Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. Journal of Pharmacology and Experimental Therapeutics 2011 337 3 766 774 10.1124/jpet.110.177790 2-s2.0-79956199678
8. Schechter J., Goldsmith P., Wilson C., Weiner R., Morphological evidence for the presence of arteries in human prolactinomas. The Journal of Clinical Endocrinology & Metabolism 1988 67 4 713 719 10.1210/jcem-67-4-713 2-s2.0-0023750110
9. Kelly M. A., Rubinstein M., Asa S. L., Zhang G., Saez C., Bunzow J. R., Allen R. G., Hnasko R., Ben-Jonathan N., Grandy D. K., Low M. J., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997 19 1 103 113 10.1016/S0896-6273(00)80351-7 2-s2.0-0030838736
10. Millan M. I. P., Luque G. M., Ramirez M. C., Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice. Endocrinology 2014 155 3 829 839 10.1210/en.2013-1707 2-s2.0-84896810616
11. Hoeben A., Landuyt B., Highley M. S., Wildiers H., van Oosterom A. T., de Bruijn E. A., Vascular endothelial growth factor and angiogenesis. Pharmacological Reviews 2004 56 4 549 580 10.1124/pr.56.4.3 2-s2.0-10644279947
12. Gerber H.-P., McMurtrey A., Kowalski J., Yan M., Keyt B. A., Dixit V., Ferrara N., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. The Journal of Biological Chemistry 1998 273 46 30336 30343 10.1074/jbc.273.46.30336 2-s2.0-0032515047
13. Ochoa A. L., Mitchner N. A., Paynter C. D., Morris R. E., Ben-Jonathan N., Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. Journal of Endocrinology 2000 165 2 483 492 10.1677/joe.0.1650483 2-s2.0-0034118693
14. Vidal S., Lloyd R. V., Moya L., Scheithauer B. W., Kovacs K., Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. Journal of Histochemistry and Cytochemistry 2002 50 4 533 540 10.1177/002215540205000410 2-s2.0-0036199393
15. Banerjee S. K., Zoubine M. N., Tran T. M., Weston A. P., Campbell D. R., Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. International Journal of Oncology 2000 16 2 253 260 2-s2.0-0034131998
16. Kim K., Yoshida D., Teramoto A., Expression of hypoxia-inducible factor 1 α and vascular endothelial growth factor in pituitary adenomas. Endocrine Pathology 2005 16 2 115 121 10.1385/EP:16:2:115 2-s2.0-25844433658
17. Onofri C., Carbia Nagashima A., Schaaf L., Feirer M., Lohrer P., Stummer W., Berner S., Chervin A., Goldberg V., Stalla G. K., Renner U., Arzt E., Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas. Experimental and Clinical Endocrinology and Diabetes 2004 112 1 18 23 10.1055/s-2004-815722 2-s2.0-10744230664
18. Banerjee S. K., Sarkar D. K., Weston A. P., De A., Campbell D. R., Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 1997 18 6 1155 1161 10.1093/carcin/18.6.1155 2-s2.0-0031408416
19. Lloyd R. V., Scheithauer B. W., Kuroki T., Vidal S., Kovacs K., Stefaneanu L., Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocrine Pathology 1999 10 3 229 235 10.1007/BF02738884 2-s2.0-0032752125
20. Viacava P., Gasperi M., Acerbi G., Manetti L., Cecconi E., Bonadio A. G., Naccarato A. G., Acerbi F., Parenti G., Lupi I., Genovesi M., Martino E., Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. Journal of Endocrinological Investigation 2003 26 1 23 28 10.1007/BF03345118 2-s2.0-0037214928
21. Sánchez-Ortiga R., Sánchez-Tejada L., Moreno-Perez O., Riesgo P., Niveiro M., Picó Alfonso A. M., Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 2013 16 3 370 377 10.1007/s11102-012-0434-4 2-s2.0-84881369135
22. McCabe C. J., Boelaert K., Tannahill L. A., Heaney A. P., Stratford A. L., Khaira J. S., Hussain S., Sheppard M. C., Franklyn J. A., Gittoes N. J. L., Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 2002 87 9 4238 4244 10.1210/jc.2002-020309 2-s2.0-18544383958
23. Cristina C., Perez-Millan M. I., Luque G., Dulce R. A., Sevlever G., Berner S. I., Becu-Villalobos D., VEGF and CD31 association in pituitary adenomas. Endocrine Pathology 2010 21 3 154 160 10.1007/s12022-010-9119-6 2-s2.0-77956472773
24. Lohrer P., Gloddek J., Hopfner U., Losa M., Uhl E., Pagotto U., Stalla G. K., Renner U., Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 2001 74 2 95 105 10.1159/000054675 2-s2.0-0034898543
25. Xie W., Wang H., He Y., Li D., Gong L., Zhang Y., CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: Relationship to VEGF expression. International Journal of Biological Sciences 2014 10 2 192 199 10.7150/ijbs.7770 2-s2.0-84893465051
26. Arita K., Kurisu K., Tominaga A., Sugiyama K., Eguchi K., Hama S., Yoshioka H., Yamasaki F., Kanou Y., Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma. Hiroshima Journal of Medical Sciences 2004 53 2 23 27 2-s2.0-4544308882
27. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G., Structural characterization and biological functions of fibroblast growth factor. Endocrine Reviews 1987 8 2 95 114 10.1210/edrv-8-2-95 2-s2.0-0023335817
28. Li Y., Koga M., Kasayama S., Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas. The Journal of Clinical Endocrinology & Metabolism 1992 75 6 1436 1441 10.1210/jc.75.6.1436 2-s2.0-0026621645
29. Arnaud E., Touriol C., Boutonnet C., Gensac M.-C., Vagner S., Prats H., Prats A.-C., A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Molecular and Cellular Biology 1999 19 1 505 514 2-s2.0-0032938857
30. Moscatelli D., High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. Journal of Cellular Physiology 1987 131 1 123 130 10.1002/jcp.1041310118 2-s2.0-0023269163
31. Ferrara N., Schweigerer L., Neufeld G., Mitchell R., Gospodarowicz D., Pituitary follicular cells produce basic fibroblast growth factor. Proceedings of the National Academy of Sciences of the United States of America 1987 84 16 5773 5777 10.1073/pnas.84.16.5773 2-s2.0-0023395778
32. Schechter J., Weiner R., Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitaries of Fisher 344 and Sprague-Dawley rats. Endocrinology 1991 129 5 2400 2408 10.1210/endo-129-5-2400 2-s2.0-0025719739
33. Heaney A. P., Fernando M., Melmed S., Functional role of estrogen in pituitary tumor pathogenesis. Journal of Clinical Investigation 2002 109 2 277 283 10.1172/JCI200214264 2-s2.0-0036153636
34. Heaney A. P., Horwitz G. A., Wang Z., Singson R., Melmed S., Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Medicine 1999 5 11 1317 1321 10.1038/15275 2-s2.0-0032742157
35. Zimering M. B., Katsumata N., Sato Y., Brandi M. L., Aurbach G. D., Marx S. J., Friesen H. G., Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. Journal of Clinical Endocrinology and Metabolism 1993 76 5 1182 1187 2-s2.0-0027243609
36. Mallea-Gil M. S., Cristina C., Perez-Millan M. I., Villafañe A. M. R., Ballarino C., Stalldecker G., Becu-Villalobos D., Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocrine Pathology 2009 20 1 35 40 10.1007/s12022-009-9057-3 2-s2.0-66349120511
37. McCabe C. J., Khaira J. S., Boelaert K., Heaney A. P., Tannahill L. A., Hussain S., Mitchell R., Olliff J., Sheppard M. C., Franklyn J. A., Gittoes N. J. L., Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology 2003 58 2 141 150 10.1046/j.1365-2265.2003.01598.x 2-s2.0-0037322597
38. Fukui S., Otani N., Nawashiro H., Yano A., Nomura N., Miyazawa T., Ohnuki A., Tsuzuki N., Katoh H., Ishihara S., Shima K., Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathology 2002 19 1 23 29 10.1007/BF02482452 2-s2.0-0036390714
39. Shimon I., Hüttner A., Said J., Spirina O. M., Melmed S., Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Journal of Clinical Investigation 1996 97 1 187 195 10.1172/JCI118388 2-s2.0-0030061454
40. Gonsky R., Herman V., Melmed S., Fagin J., Transforming DNA sequences present in human prolactin-secreting pituitary tumors. Molecular Endocrinology 1991 5 11 1687 1695 10.1210/mend-5-11-1687 2-s2.0-0025724116
41. Zou H., McGarry T. J., Bernal T., Kirschner M. W., Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999 285 5426 418 421 10.1126/science.285.5426.418 2-s2.0-0033575347
42. Yu R., Melmed S., Pituitary tumor transforming gene an update. Frontiers of Hormone Research 2004 32 175 185 10.1159/000079044 2-s2.0-4043059447
43. Cristina C., Díaz-Torga G. S., Goya R. G., Kakar S. S., Perez-Millán M. I., Passos V. Q., Giannella-Neto D., Bronstein M. D., Becu-Villalobos D., PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Molecular Cancer 2007 6, article 4 10.1186/1476-4598-6-4 2-s2.0-33846881146
44. Xiao J.-Q., Liu X.-H., Hou B., Yao Y., Deng K., Feng M., Xing B., Lian W., Wang R.-Z., Feng F., Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis. PLoS ONE 2014 9 3 e90396 10.1371/journal.pone.0090396 2-s2.0-84897031081
45. Ren B., Yee K. O., Lawler J., Khosravi-Far R., Regulation of tumor angiogenesis by thrombospondin-1. Biochimica et Biophysica Acta: Reviews on Cancer 2006 1765 2 178 188 10.1016/j.bbcan.2005.11.002 2-s2.0-33646136232
46. Sarkar A. J., Chaturvedi K., Chen C. P., Sarkar D. K., Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors. Journal of Endocrinology 2007 192 2 395 403 10.1677/joe.1.06925 2-s2.0-33947376565
47. Recouvreux M. V., Camilletti M. A., Rifkin D. B., Becu-Villalobos D., Díaz-Torga G., Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor- β 1 (TGF- β 1). Endocrinology 2012 153 8 3861 3871 10.1210/en.2012-1007 2-s2.0-84864389692
48. Ezzat S., The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathology 2001 11 3 356 370 2-s2.0-0034980120
49. Niveiro M., Aranda F. I., Peiró G., Alenda C., Picó A., Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Human Pathology 2005 36 10 1090 1095 10.1016/j.humpath.2005.07.015 2-s2.0-26644447156
50. Itoh J., Serizawa A., Kawai K., Ishii Y., Teramoto A., Osamura R. Y., Vascular networks and endothelial cells in the rat experimental pituitary glands and in the human pituitary adenomas. Microscopy Research and Technique 2003 60 2 231 235 10.1002/jemt.10261 2-s2.0-0037302810
51. Pawlikowski M., Pisarek H., Jaranowska M., Immunocytochemical investigations on the vascularization of pituitary adenomas. Endocrine Pathology 1997 8 3 189 193 10.1007/BF02738785 2-s2.0-0000765287
52. Vidal S., Kovacs K., Horvath E., Scheithauer B. W., Kuroki T., Lloyd R. V., Microvessel density in pituitary adenomas and carcinomas. Virchows Archiv 2001 438 6 595 602 10.1007/s004280000373 2-s2.0-0034912507
53. Takada K., Yamada S., Teramoto A., Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocrine Pathology 2004 15 2 131 139 10.1385/EP:15:2:131 2-s2.0-4444308933
54. Matano F., Yoshida D., Ishii Y., Tahara S., Teramoto A., Morita A., Endocan, a new invasion and angiogenesis marker of pituitary adenomas. Journal of Neuro-Oncology 2014 117 3 485 491 10.1007/s11060-014-1377-6 2-s2.0-84901285655
55. Pizarro C. B., Oliveira M. C., Pereira-Lima J. F. S., Leães C. G. S., Kramer C. K., Schuch T., Barbosa-Coutinho L. M., Ferreira N. P., Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathology 2009 29 1 40 44 10.1111/j.1440-1789.2008.00937.x 2-s2.0-58449123335
56. Turner H. E., Nagy Z. S., Gatter K. C., Esiri M. M., Wass J. A. H., Harris A. L., Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. British Journal of Cancer 2000 82 8 1441 1445 10.1054/bjoc.1999.1074 2-s2.0-0034068226
57. Turner H. E., Harris A. L., Melmed S., Wass J. A., Angiogenesis in endocrine tumors. Endocrine Reviews 2003 24 5 600 632 10.1210/er.2002-0008 2-s2.0-0142217202
58. Nör J. E., Christensen J., Mooney D. J., Polverini P. J., Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. The American Journal of Pathology 1999 154 2 375 384 10.1016/S0002-9440(10)65284-4 2-s2.0-0032963472
59. Perez-Millan M. I., Berner S. I., Luque G. M., Enhanced nestin expression and small blood vessels in human pituitary adenomas. Pituitary 2013 16 3 303 310 10.1007/s11102-012-0421-9 2-s2.0-84881367483
60. Smith-McCune K. K., Weidner N., Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Research 1994 54 3 800 804 2-s2.0-0027958101
61. Brem S. S., Jensen H. M., Gullino P. M., Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978 41 1 239 244 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO;2-X 2-s2.0-0017842951
62. Poncelet C., Madelenat P., Feldmann G., Walker F., Darai E., Expression of von willebrand's factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertility and Sterility 2002 78 3 581 586 10.1016/S0015-0282(02)03301-0 2-s2.0-0036732182
63. de La Torre N. G., Buley I., Wass J. A. H., Turner H. E., Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocrine-Related Cancer 2006 13 3 931 944 10.1677/erc.1.01210 2-s2.0-33751095944
64. Jasek E., Furgal-Borzych A., Lis G. J., Litwin J. A., Rzepecka-Wozniak E., Trela F., Microvessel density and area in pituitary microadenomas. Endocrine Pathology 2009 20 4 221 226 10.1007/s12022-009-9091-1 2-s2.0-70449528504
65. Mokrý J., Ehrmann J., Karbanová J., Cízková D., Soukup T., Suchánek J., Filip S., Kolár Z., Expression of intermediate filament nestin in blood vessels of neural and non-neural tissues. Acta Medica 2008 51 3 173 179 2-s2.0-63249095014
66. Lendahl U., Zimmerman L. B., McKay R. D. G., CNS stem cells express a new class of intermediate filament protein. Cell 1990 60 4 585 595 10.1016/0092-8674(90)90662-X 2-s2.0-0025190642
67. Gautron L., de-Smedt V., Layé S., Age-related changes in nestin immunoreactivity in the rat pituitary gland. Neuroendocrinology 2009 90 1 19 30 10.1159/000220994 2-s2.0-67651111842
68. Rotondo F., Kovacs K., Horvath E., Bell C. D., Lloyd R. V., Scheithauer B. W., Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms. Acta Neuropathologica 2006 111 3 272 277 10.1007/s00401-006-0031-6 2-s2.0-33645580280
69. Veselska R., Kuglik P., Cejpek P., Svachova H., Neradil J., Loja T., Relichova J., Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 2006 6, article 32 10.1186/1471-2407-6-32 2-s2.0-33645017201
70. Gravdal K., Halvorsen O. J., Haukaas S. A., Akslen L. A., Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Research 2009 69 11 4708 4715 10.1158/0008-5472.CAN-08-4417 2-s2.0-66349115001
71. Mokrý J., Čížková D., Filip S., Nestin expression by newly formed human blood vessels. Stem Cells and Development 2004 13 6 658 664 10.1089/scd.2004.13.658 2-s2.0-11144248873
72. Klein T., Ling Z., Heimberg H., Madsen O. D., Heller R. S., Serup P., Nestin is expressed in vascular endothelial cells in the adult human pancreas. Journal of Histochemistry & Cytochemistry 2003 51 6 697 706 10.1177/002215540305100601 2-s2.0-0038012893
73. Sugawara K.-I., Kurihara H., Negishi M., Saito N., Nakazato Y., Sasaki T., Takeuchi T., Nestin as a marker for proliferative endothelium in gliomas. Laboratory Investigation 2002 82 3 345 351 10.1038/labinvest.3780428 2-s2.0-0036129254
74. Salehi F., Kovacs K., Cusimano M. D., Horvath E., Bell C. D., Rotondo F., Scheithauer B. W., Immunohistochemical expression of nestin in adenohypophysial vessels during development of pituitary infarction: laboratory investigation. Journal of Neurosurgery 2008 108 1 118 123 10.3171/JNS/2008/108/01/0118 2-s2.0-38149019803
75. Basu S., Nagy J. A., Pal S., Vasile E., Eckelhoefer I. A., Bliss V. S., Manseau E. J., Dasgupta P. S., Dvorak H. F., Mukhopadhyay D., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Medicine 2001 7 5 569 574 10.1038/87895 2-s2.0-0035026748
76. Teunis M. A. T., Kavelaars A., Voest E., Bakker J. M., Ellenbroek B. A., Cools A. R., Heijnen C. J., Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. The FASEB Journal 2002 16 11 1465 1467 2-s2.0-0036717151
77. Caccavelli L., Feron F., Morange I., Rouer E., Benarous R., Dewailly D., Jaquet P., Kordon C., Enjalbert A., Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994 60 3 314 322 10.1159/000126764 2-s2.0-0028170513
78. Molitch M. E., Pharmacologic resistance in prolactinoma patients. Pituitary 2005 8 1 43 52 10.1007/s11102-005-5085-2 2-s2.0-33644870544
79. Caccavelli L., Morange-Ramos I., Kordon C., Jaquet P., Enjalbert A., Alteration of G α subunits mRNA levels in bromocriptine resistant prolactinomas. Journal of Neuroendocrinology 1996 8 10 737 746 10.1046/j.1365-2826.1996.04902.x 2-s2.0-0029740654
80. Pellegrini I., Rasolonjanahary R., Gunz G., Bertrand P., Delivet S., Jedynak C. P., Kordon C., Peillon F., Jaquet P., Enjalbert A., Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 1989 69 3 500 509 10.1210/jcem-69-3-500 2-s2.0-0024466634
81. Cristina C., García-Tornadú I., Díaz-Torga G., Rubinstein M., Low M. J., Becú-Villalobos D., Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma. Frontiers of Hormone Research 2006 35 50 63 10.1159/000094308 2-s2.0-33745795815
82. Asa S. L., Kelly M. A., Grandy D. K., Low M. J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 1999 140 11 5348 5355 2-s2.0-0033303537
83. Díaz-Torga G., Feierstein C., Libertun C., Gelman D., Kelly M. A., Low M. J., Rubinstein M., Becú-Villalobos D., Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology 2002 143 4 1270 1279 10.1210/en.143.4.1270 2-s2.0-0036212322
84. García-Tornadú I., Rubinstein M., Gaylinn B. D., Hill D., Arany E., Low M. J., Díaz-Torga G., Becu-Villalobos D., GH in the dwarf dopaminergic D2 receptor knockout mouse: somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin. Journal of Endocrinology 2006 190 3 611 619 10.1677/joe.1.06902 2-s2.0-33749823844
85. Noaín D., Pérez-Millán M. I., Bello E. P., Luque G. M., Cordero R. C., Gelman D. M., Peper M., Tornadu I. G., Low M. J., Becú-Villalobos D., Rubinstein M., Central dopamine D2 receptors regulate growth-hormone- dependent body growth and pheromone signaling to conspecific males. The Journal of Neuroscience 2013 33 13 5834 5842 10.1523/JNEUROSCI.5673-12.2013 2-s2.0-84875467596
86. Cristina C., Díaz-Torga G., Baldi A., Góngora A., Rubinstein M., Low M. J., Becú-Villalobos D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 2005 146 7 2952 2962 10.1210/en.2004-1445 2-s2.0-22144499643
87. Cristina C., Díaz-Torga G., Góngora A., Guida M. C., Perez-Millán M. I., Baldi A., Becu-Villalobos D., Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice. The American Journal of Physiology-Endocrinology and Metabolism 2007 293 5 E1341 E1351 10.1152/ajpendo.00260.2007 2-s2.0-36148950965
88. Crawford Y., Ferrara N., VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research 2009 335 1 261 269 10.1007/s00441-008-0675-8 2-s2.0-57749173152
89. Ferrara N., Pathways mediating VEGF-independent tumor angiogenesis. Cytokine and Growth Factor Reviews 2010 21 1 21 26 10.1016/j.cytogfr.2009.11.003 2-s2.0-77549088772
90. Kerbel R. S., Tumor angiogenesis. The New England Journal of Medicine 2008 358 19 2039 2049 10.1056/NEJMra0706596 2-s2.0-43249095919
91. Burris H. III, Rocha-Lima C., New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008 13 3 289 298 10.1634/theoncologist.2007-0134 2-s2.0-43549094700
92. Korsisaari N., Ross J., Wu X., Kowanetz M., Pal N., Hall L., Eastham-Anderson J., Forrest W. F., Van Bruggen N., Peale F. V., Ferrara N., Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clinical Cancer Research 2008 14 1 249 258 10.1158/1078-0432.CCR-07-1552 2-s2.0-40749138225
93. Shan B., Schaaf C., Schmidt A., Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. Journal of Endocrinology 2012 214 3 389 398 10.1530/JOE-12-0207 2-s2.0-84866295392
94. Ortiz L. D., Syro L. V., Scheithauer B. W., Ersen A., Uribe H., Fadul C. E., Rotondo F., Horvath E., Kovacs K., Anti-VEGF therapy in pituitary carcinoma. Pituitary 2012 15 3 445 449 10.1007/s11102-011-0346-8 2-s2.0-84867398371
95. Asa S. L., Ezzat S., The pathogenesis of pituitary tumours. Nature Reviews Cancer 2002 2 11 836 849 10.1038/nrc926 2-s2.0-0036831826
96. Melmed S., Mechanisms for pituitary tumorigenesis: the plastic pituitary. The Journal of Clinical Investigation 2003 112 11 1603 1618 10.1172/JCI200320401 2-s2.0-0347951038
97. Renner U., Pagotto U., Arzt E., Stalla G. K., Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. European Journal of Endocrinology 1996 135 5 515 532 10.1530/eje.0.1350515 2-s2.0-0029955062